Get the Stockscreener App
1.65
1.79%
-0.03
After Hours:
1.65
Silexion Therapeutics Corp stock is traded at $1.65, with a volume of 30,835.
It is down -1.79% in the last 24 hours and up +9.27% over the past month.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$1.68
Open:
$1.65
24h Volume:
30,835
Relative Volume:
0.72
Market Cap:
$5.50M
Revenue:
-
Net Income/Loss:
$-17.85M
P/E Ratio:
-0.0445
EPS:
-37.0644
Net Cash Flow:
$-13.02M
1W Performance:
-5.17%
1M Performance:
+9.27%
6M Performance:
-76.92%
1Y Performance:
-92.41%
1-Day Range:
$1.62
$1.70
1-Week Range:
$1.62
$1.75
52-Week Range:
$1.42
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.65 | 5.60M | 0 | -17.85M | -13.02M | -37.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting - Bitget
Cancer biotech Silexion seeks to authorize 50M more shares - Stock Titan
Rally Mode: Is Silexion Therapeutics Corp a defensive stock2025 Price Targets & Entry and Exit Point Strategies - baoquankhu1.vn
SLXN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Book value per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
EPS Watch: Is First Light Acquisition Group Inc Equity Warrant vulnerable to short sellersQuarterly Portfolio Report & Smart Allocation Stock Tips - baoquankhu1.vn
SLXNW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SLXN Should I Buy - Intellectia AI
EBITDA per share of Silexion Therapeutics Corp – NASDAQ:SLXNW - TradingView
Market Fear: Should value investors consider CompoSecure Inc Equity WarrantMarket Activity Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Director Alon Ruth receives Silexion (SLXN) share and stock option grants - Stock Titan
Silexion Therapeutics (SLXN) CFO receives 49,726-share equity grant - Stock Titan
Silexion (SLXN) CEO Hadar Ilan receives 64,350-share equity award - Stock Titan
Director at Silexion Therapeutics (SLXN) receives new share and option grants - Stock Titan
Silexion Therapeutics (SLXN) director granted 7,576 shares and 8,904 options - Stock Titan
Guangzhou Sino-Israel Biotech Fund gains SLXN equity for board service - Stock Titan
Ideas Watch: Is Olympic Steel Inc forming a breakout patternOptions Play & Weekly High Conviction Trade Ideas - baoquankhu1.vn
SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Will Silexion Therapeutics Corp benefit from geopolitical trendsDip Buying & AI Powered Buy/Sell Recommendations - mfd.ru
Can Silexion Therapeutics Corp Equity Warrant reach resistance levels soonWeekly Trend Recap & Expert Verified Movement Alerts - mfd.ru
Price Action: How volatile is Silexion Therapeutics Corp stockBull Run & Weekly Return Optimization Plans - baoquankhu1.vn
Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN) By FinanceWire - Investing.com
Silexion Therapeutics is developing a potential “holy grail” play in precision oncology (NASDAQ: SLXN) - TipRanks
Stock Report: Is Silexion Therapeutics Corp Equity Warrant stock forming a triangle patternWall Street Watch & Community Shared Stock Ideas - mfd.ru
Can Silexion Therapeutics Corp Equity Warrant stock deliver strong Q4 earningsQuarterly Portfolio Report & AI Enhanced Market Trend Forecasts - mfd.ru
S P Trends: Will CIMPRD benefit from rate cuts2025 Price Momentum & Daily Price Action Insights - baoquankhu1.vn
Momentum Shift: Should I hold or sell Silexion Therapeutics Corp now2025 Trading Volume Trends & Fast Gain Swing Alerts - baoquankhu1.vn
Can Silexion Therapeutics Corp sustain its profitability2025 Big Picture & Proven Capital Preservation Methods - mfd.ru
What’s the beta of Silexion Therapeutics Corp Equity Warrant stockJuly 2025 Highlights & Daily Risk Controlled Trade Plans - mfd.ru
Is Silexion Therapeutics Corp stock affected by interest rate hikesMarket Activity Recap & Fast Gain Stock Tips - mfd.ru
What’s the profit margin of Silexion Therapeutics CorpAnalyst Upgrade & Safe Entry Trade Reports - mfd.ru
Trading Recap: Will Silexion Therapeutics Corp Equity Warrant benefit from government policyQuarterly Trade Report & Short-Term High Return Strategies - baoquankhu1.vn
Analyst Downgrade: Can Silexion Therapeutics Corp be recession proofMarket Trend Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Silexion Highlights SIL204 RNAi Pancreatic Cancer Program Progress - TipRanks
Silexion Therapeutics Corp Prepares Investor Presentation on SIL204 - TradingView
Jobs Data: What is ALBTs P E ratio telling us2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Swing Trade: What is the earnings history of Claritev Corporation2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Opening: Will Silexion Therapeutics Corp Equity Warrant benefit from government policyQuarterly Profit Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Gap Down: Can Silexion Therapeutics Corp be recession proofQuarterly Risk Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Risk Hedge: Can Spring Valley Acquisition Corp II Equity Warrant sustain its profitability2025 Biggest Moves & Reliable Entry Point Alerts - baoquankhu1.vn
Investment Review: Can Silexion Therapeutics Corp Equity Warrant expand its profit marginsQuarterly Performance Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Silexion shares skyrocket 400% after encouraging pancreatic cancer drug results - MSN
Growth Value: What is the implied volatility of Silexion Therapeutics Corp2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - manilatimes.net
Silexion Therapeutics to Participate in 7th RNAi-Based Therapeutics Summit Focused on Advancing SIL204 for Pancreatic Cancer - Quiver Quantitative
Retail Surge: Whats the RSI of Kirby Corporation stock2025 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Silexion reports breakthrough in KRAS cancer therapy - MSN
Signal Recap: What is the PEG ratio of Silexion Therapeutics Corp Equity Warrant2025 Key Lessons & Detailed Earnings Play Strategies - baoquankhu1.vn
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Opening Moves & Fast Gain Swing Alerts - ulpravda.ru
Why Silexion Therapeutics Corp Equity Warrant stock attracts high net worth investorsFit and Size Notes & quick comparison of popular models - Улправда
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):